2013
Tyrosine-kinase inhibitors in oncology
Tsao A, Papadimitrakopoulou V, Herbst R. Tyrosine-kinase inhibitors in oncology. 2013, 872-883. DOI: 10.1017/cbo9781139046947.083.Peer-Reviewed Original ResearchHigh-throughput technologiesKey oncogenic pathwaysGenomic eraMechanistic targetComplexity of cancerOncogenic pathwaysMolecular perspectiveHuman cancersMolecular oncologyMolecular changesHuman malignanciesPathwayCancer tissuesCritical driverTyrosine kinase inhibitorsMalignant transformationNew discoveriesGenomicsDiscoveryGenesMutationsEnormous stridesNew drugsInhibitorsCancer
2006
Therapeutic options to target angiogenesis in human malignancies
Herbst RS. Therapeutic options to target angiogenesis in human malignancies. Expert Opinion On Emerging Drugs 2006, 11: 635-650. PMID: 17064223, DOI: 10.1517/14728214.11.4.635.Peer-Reviewed Original ResearchConceptsTyrosine kinase inhibitorsHuman malignanciesMonoclonal antibodiesGrowth factorKinase inhibitorsAnti-VEGF inhibitorsGastrointestinal stromal tumorsSolid human malignanciesRenal cell carcinomaBasic fibroblast growth factorRole of VEGFTypes of cancerFibroblast growth factorStromal tumorsTherapeutic optionsCell carcinomaColorectal cancerAntiangiogenic drugsClinical trialsDrug classesPro-angiogenic growth factorsSmall molecule inhibitorsTumor growthTumor angiogenesisMatrix breakdown